Little is known of the effect of endogenously secreted GLP-1 on NAFLD, but GLP-1 receptor agonists inhibit de novo lipogenesis in the liver (i.e., from glucose) and may thereby reduce steatosis [31]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.